Daniel R. Kuritzkes, MD

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss the likelihood of other combination regimens for the treatment of multidrug-resistant HIV, including monoclonal antibodies.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss the implications of recent data regarding the use of fostemsavir and ibalizumab.

Daniel R. Kuritzkes, MD, describes how the unique mechanism of lenacapavir allows clinicians to maintain viral inhibition over time.

Joseph Eron, MD, and Monica Gandhi, MD, MPH, describe the obstacles to treatment efficacy with the available treatment options.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, explore the relative pros and cons of various agents and drug classes that may be used for the treatment of multi-drug resistant HIV.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, share recommendations to improve pre-therapy resistance testing in community settings.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, review strategies for determining whether drug resistance is the primary reason for suboptimal treatment response or adherence.

Thought leaders discuss when and how to approach drug resistance and steps to ensure long-term treatment success.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss factors that shape treatment approaches, including tolerability and treatment adherence.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, explore the ways in which drug-resistance mutations impact treatment efficacy.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, examine the many factors associated with increased risk of HIV, including substance abuse, unstable housing/food situations, and mental illness.

Joseph Eron, MD and Daniel R. Kuritzkes, MD, discuss how to define “heavily treatment-experienced” and also discuss the prevalence of various types of drug resistance.